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Background
The antibodies that block immunological checkpoints
have been successfully applied for the treatment of cancer.
Similar effects are expected by molecular targeted therapy,
which primarily aims to inhibit molecular pathways for
tumor cell growth and survival. Such small molecular
drugs may modulate the immune system, which raises the
possibility that targeted therapy might be effectively com-
bined with immunotherapy. Sunitinib, a tyrosine kinase
inhibitor currently in use for the treatment of metastatic
renal cell carcinoma (mRCC), has been reported to modu-
late immunosuppressive cells such as myeloid-derived
suppressor cells (MDSCs) and regulatory T cells (Tregs).
We conducted a clinical study of dendritic cell (DC)-based
immunotherapy together with Sunitinib in mRCC patients
in an effort to enhance immunotherapeutic efficacy by
inhibiting immunosuppressive cells.
Methods
Patients aged ≥20 years with advanced or recurrent mRCC
who underwent nephrectomy were eligible for this study.
Autologous tumor samples were obtained by surgery and
used for preparing autologous tumor lysate. Leukapheresis
was performed to obtain peripheral blood mononuclear
cells (PBMCs). DCs were generated from adherent
PBMCs in the presence of recombinant human granulo-
cyte macrophage colony-stimulating factor (GM-CSF)
(500 IU/ml) and IL-4 (500 IU/ml). Mature DCs were
loaded with autologous tumor lysate by electroporation.
Eight patients were enrolled in the study and received
Sunitinib at a dose of 50 mg p.o. daily for 28 days fol-
lowed by 14 days of rest. Tumor lysate-loaded DCs were
administered subcutaneously every two weeks, with
concomitant Sunitinib.
Results
No severe adverse events related to vaccination were
observed. Sunitinib decreased the frequencies of MDSCs
in peripheral blood of 5 patients and of Tregs in 3. Tumor
lysate-reactive CD4 or CD8 T cell responses were
observed in 5 patients, 4 of whom showed decreased
frequencies of Tregs and/or MDSCs. The remaining
3 patients who failed to develop tumor-reactive T cell
responses had high levels of IL-8 in their sera and did not
show consistent reductions in MDSCs and Tregs. The
antigen spreading was observed; the production of antibo-
dies against several cancer testis antigen was induced after
DC vaccination. The median overall survival was 346 days
and median progression-free survival was 164 days. One
patient achieved a complete response, another patient had
a partial response, 2 had stable disease and 3 had progres-
sive disease according to the RECIST (one N/A).
Conclusions
DC-based immunotherapy combined with Sunitinib is
safe and feasible for patients with mRCC.
Trial registration
Trial registration number: UMIN000002136
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